HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHPA Agenda 2014: Monograph Reform, NSURE Progress

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association plans to tackle big tasks in 2014, including working with FDA to improve the monograph system, move the new Rx-to-OTC switch paradigm forward and determine quality metrics to help FDA better target inspections. The trade group also is looking for ways to ease pricing pressures and ensure quality does not suffer.

You may also be interested in...



House Pushes FDA To Expedite Sunscreen Ingredient Reviews

Reps. Dingell and Whitfield ask for FDA’s assistance on legislation they are writing to expedite the agency’s review of additional sunscreen ingredients. CDER Director Woodcock pledges FDA help, but explains the agency’s OTC ingredient reviews are “backlogged.”

Sanofi’s Nasacort First-In-Class Switch Receives FDA Approval

The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.

CHPA Petitions For Acetaminophen Under-2 Dose Labeling

CHPA urges FDA not to wait until it publishes the final internal analgesics, antipyretic and anti-rheumatic monograph before allowing manufacturers to label acetaminophen products with dosing information for children 6 months to 2 years old. In a citizen petition, the trade group proposes FDA publish a statement of enforcement policy expressly permitting the use of a standardized age- and weigh-based dosing chart.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS026881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel